why choose us

First received: March 09, 2023

Clinical Trial: Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism

Study Status: Completed

Recruit Status: RECRUITING

Condition: Chronic Hypoparathyroidism

Study Type: INTERVENTIONAL


Official Title: A Phase 3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Eneboparatide (AZP-3601), a Parathyroid Hormone Receptor Agonist, in Patients With Chro

Brief Summary: This study is investigating the safety and efficacy of eneboparatide (AZP-3601) in patients with chronic hypoparathyroidism (cHP).During the first 24 weeks of the trial, participants will be randomized to receive eneboparatide or placebo.Study treatment is blinded: patients and doctors will not know which group each patient has been randomized to.All patients will start with a fixed dose of study treatment (eneboparatide or placebo), administered subcutaneously with a pre-filled pen.Study treatment will be…

Read more